Project Grant K08HD113835

Award Date 7/1/24
Completion Date 10/31/27
Dollars Obligated $515K
Federal Grant Program
93.865
Assistance Type
Project Grant
Place of Performance
Utah, USA
Similar Awards
This $153,252 Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) supports research to develop strategies for identifying individuals at high risk for genetic diseases in order to enable earlier diagnosis and treatment. The award has two key aims: 1) Reevaluating guidelines for universal preconception carrier screening to improve uptake and include new actionable...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), funds the development and validation of a machine learning-based fetal monitoring system to predict and prevent fetal hypoxia. The $261,310 award will support the creation of a high-sensitivity, high-specificity predictive model using a multi-site dataset of 50,000 fetal monitoring tracings coupled with...
This Project Grant award, funded by the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865), will support research to develop non-invasive magnetic resonance imaging (MRI) techniques to predict fetal growth early in pregnancy. The $295,212 award, with a project period from September 1, 2024 to August 31, 2026, will be used by the University of South Australia to conduct a preclinical study in...
This $2,442,535 Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865) will fund research to understand the long-term impact and value of implementing newborn genomic sequencing. The key objectives are to: Conduct interviews with clinicians, health system leaders, and newborn screening program coordinators to understand their needs and concerns regarding integrating newborn genomic sequencing with traditional screening programs. Follow up with...
This $661,258 Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), supports a multi-faceted initiative to improve clinical evaluation, data collection, and predictive modeling for stillbirth. The key objectives are to: 1) standardize clinical evaluation, genetic testing, and data collection for stillbirth cases across the University of Washington (UW) hospital...
This Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) is focused on generating strategies and resources to facilitate informed decision-making for pregnant patients regarding prenatal genetic screening and diagnostic tests (PS&D). The $831,046 award, effective September 18, 2024 through August 31, 2025, aims to: Determine how changes in PS&D and post-diagnosis options affect the resources and support patients need for informed...
This Project Grant award from the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality (AHRQ) under the CFDA 93.226 Research on Healthcare Costs, Quality and Outcomes program is funding the development and testing of a clinical decision support (CDS) tool to improve iron deficiency screening and management for pregnant individuals at high risk of postpartum hemorrhage (PPH). Specifically, the $118,089 award will support a two-phase project at Massachusetts...
This Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) aims to develop novel statistical models for multi-trait analysis in large-scale biobank datasets linked to electronic health records. The $122,234 award, effective from September 20, 2024 to August 31, 2026, will support research at Columbia University's Health Sciences Division to enhance disease association mapping and risk prediction accuracy. Specifically, the project will: 1)...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), will provide $102,168 to support a research study conducted by the University of California, San Francisco (UCSF). The study aims to evaluate the effects of state-level initiatives to reduce early-term elective deliveries (EEDS) on maternal and newborn outcomes, as well as disparities in these outcomes. The...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) aims to investigate the effects of maternal medication exposures on early life health outcomes in children. The $108,512.00 award to the University of Chicago, granted on Nov 22, 2025, will fund a three-part research effort: Building a high-quality registry of mother-child pairs by extracting additional phenotype...

INDIVIDUALIZATION OF FETAL GROWTH ASSESSMENT USING MATERNAL GENETICS AND EXPLAINABLE AI - ABSTRACT THIS IS A K08 AWARD APPLICATION FOR DR. NATHAN BLUE, A MATERNAL-FETAL MEDICINE PHYSICIAN AND YOUNG INVES- TIGATOR PURSUING TRANSLATIONAL AND CLINICAL RESEARCH TO IMPROVE RISK STRATIFICATION APPROACHES TO FETAL GROWTH RE- STRICTION (FGR). A K08 AWARD WILL PROVIDE HIM WITH THE MEANS TO ACQUIRE CRITICAL SKILLS IN THREE KEY CAREER DEVEL- OPMENT AREAS: 1) PROGRAMMING SKILLS TO CARRY OUT ANALYSES AND VISUALIZATIONS (UNIX, R, PYTHON), 2) NOVEL BIO- MEDICAL INFORMATICS APPROACHES TO QUANTIFY RISK OF ADVERSE OUTCOMES, AND 3) INTERDISCIPLINARY RESEARCH LEADER- SHIP AND MANAGEMENT. BY ACQUIRING THESE SKILLS, DR. BLUE WILL FULFILL HIS CAREER GOAL OF BECOMING AN INDEPENDENT INVESTIGATOR WHO CAN IMPROVE PRENATAL RECOGNITION OF FETUSES AT RISK OF ADVERSE OUTCOMES. TO PURSUE THIS GOAL, DR. BLUE HAS ASSEMBLED THE MENTORING TEAM OF DR. ROBERT SILVER (PRIMARY MENTOR), A MATERNAL-FETAL MEDICINE PHYSICIAN AND INTERNATIONAL AUTHORITY ON OBSTETRIC COMPLICATIONS, DR. MARK YANDELL (CO-MENTOR), A HUMAN GENET- ICS SCIENTIST, EXPERT IN COMPUTATIONAL BIOLOGY, AND DEVELOPER OF MEDICAL RISK ASSESSMENT SOFTWARE TOOLS, AND DR. MARTIN TRISTANI-FIROUZI (CO-MENTOR), A PEDIATRIC CARDIOLOGY PHYSICIAN AND WIDELY RECOGNIZED LEADER IN APPLICA- TION OF NEW INFORMATICS TOOLS TO COMPLEX CLINICAL PROBLEMS SUCH AS CONGENITAL HEART DISEASE. FETAL GROWTH RESTRICTION (FGR) IS A LEADING CAUSE OF PREVENTABLE STILLBIRTHS, POSTNATAL COMPLICATIONS, AND RE- SULTS IN A LIFELONG INCREASED RISK OF CARDIOVASCULAR DISEASE. BASED ON HIS OWN PUBLISHED DATA, DR. BLUE'S CENTRAL HYPOTHESIS IS THAT CURRENT FETAL ASSESSMENT TOOLS FUNCTION POORLY BECAUSE THEY ASSUME ALL FETUSES SHOULD BE THE SAME SIZE AND FETAL GROWTH ULTRASOUNDS ARE INTERPRETED IN ISOLATION OF OTHER FACTORS THAT COULD BE USEFUL TO INFORM RISK. HE WILL TEST THIS HYPOTHESIS BY ANALYZING MATERNAL GENETIC VARIANTS AND USING A NOVEL EXPLAINABLE ARTIFICIAL INTELLIGENCE (AI) METHOD TO DEVELOP INDIVIDUALIZED PREDICTION MODELS FOR EXPECTED FETAL GROWTH AND RISK OF PERINATAL MORBIDITY. THIS WILL UNCOVER INSIGHTS INTO NORMAL FETAL GROWTH AS WELL AS PRODUCE A NEW NEONATAL MORBIDITY RISK CALCULATOR. BY PURSUING THE FOLLOWING AIMS, DR. BLUE WILL TEST HIS HYPOTHESIS AND LAY THE GROUND- WORK FOR REFINING HIS NEW TOOLS PRIOR TO APPLICATION TO FETAL GROWTH IN A PROSPECTIVE COHORT (TO BE PROPOSED IN AN R01 APPLICATION DURING THE K08 AWARD PERIOD). SPECIFIC AIM 1 WILL TEST THE HYPOTHESIS THAT MATERNAL GENETIC INFORMATION CAN BE USED TO INDIVIDUALIZE BIRTH WEIGHT PREDICTION IN UNCOMPLICATED PREGNANCIES. SPECIFIC AIM 2 WILL TEST THE HYPOTHESIS THAT GENETICS, SPECIFIC CLINICAL VARIABLES, AND SOCIAL DETERMINANTS OF HEALTH INTERACT SYN- ERGISTICALLY TO INCREASE THE RISK OF POOR OUTCOMES IN FGR, WHICH CAN BE CAPTURED BY NEW EXPLAINABLE AI. THE PROPOSED RESEARCH IS SIGNIFICANT BECAUSE DESPITE FGR'S ENORMOUS GLOBAL BURDEN, CURRENT APPROACHES TO FETAL GROWTH ASSESSMENT CONTINUE TO PERFORM POORLY, FORCING CLINICIANS AND FAMILIES TO MAKE PLANS WITHOUT APPROPRIATELY INDIVIDUALIZED INFORMATION. THE PROPOSED RESEARCH IS INNOVATIVE BECAUSE OF ITS USE OF 1) MATERNAL GENETIC RATHER THAN CLINICAL DATA SUCH AS HEIGHT, WEIGHT, AND RACE TO PREDICT HEALTHY BIRTH WEIGHT, AND 2) EXPLAIN- ABLE AI FOR RISK STRATIFICATION RATHER THAN BLACK-BOX AI TECHNIQUES THAT ARE TOO OPAQUE FOR TRUSTWORTHY APPLICATION.

Posted 6/13/24, 12:00 AM